Melanoma Treatment with BRAF and MEK Inhibitors Increases Cardiovascular Risks - DocWire News

Melanoma Treatment with BRAF and MEK Inhibitors Increases Cardiovascular Risks  DocWire News

Melanoma patients who undergo treatment with BRAF and MEK inhibitors may be more likely to sustain cardiovascular adverse events (CVAEs) compared to ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more